Home > Research > Publications & Outputs > Study to evaluate the optimal dose of remifenta...

Electronic data

  • remi_submitted

    Submitted manuscript, 986 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

  • remi_230121_revised_final

    Rights statement: This is the peer reviewed version of the following article: Arnold, P., Sanaulla, S., Hampson, L.V., Davis, A., Tan, J., Cowen, R., Kaleem, M., Williams, A., Wadsworth, I. and Jaki, T. (2021), Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia. Pediatr Anaesth, 31: 548-556. https://doi.org/10.1111/pan.14164 which has been published in final form at https://onlinelibrary.wiley.com/doi/10.1111/pan.14164 This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

    Accepted author manuscript, 355 KB, PDF document

    Embargo ends: 16/03/22

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia

Research output: Contribution to journalJournal articlepeer-review

Published
Close
<mark>Journal publication date</mark>31/05/2021
<mark>Journal</mark>Paediatric Anesthesia
Issue number5
Volume31
Number of pages9
Pages (from-to)548-556
Publication StatusPublished
Early online date16/03/21
<mark>Original language</mark>English

Abstract

Background: Magnetic resonance (MRI) scanning of the heart is an established part of the investigation of cardiovascular conditions in children. In young children, sedation is likely to be needed, and multiple controlled periods of apnea are often required to allow image acquisition. Suppression of spontaneous ventilation is possible with remifentanil; however, the dose required is uncertain. Aims: To establish the dose of remifentanil, by infusion, required to suppress ventilation sufficiently to allow a 30-s apnea during MRI imaging of the heart. Method: Patients aged 1–6 years were exposed to different doses of remifentanil, and the success in achieving a 30-s apnea was recorded. A dose recommendation was made for each patient, informed by responses of previous patients using an adaptive Bayesian dose-escalation design. Other aspects of anesthesia were standardized. A final estimate of the dose needed to achieve a successful outcome in 80% of patients (ED80) was made using logistic regression. Results: 38 patients were recruited, and apnea achieved in 31 patients. The estimate of the ED80 was 0.184 µg/kg/min (95% CI 0.178–0.190). Post hoc analysis revealed that higher doses were required in younger patients. Conclusion: The ED80 for this indication was 0.184 µg/kg/min (95% CI 0.178–0.190). This is different from optimal dosing identified for other indications and dosing of remifentanil should be specific to the clinical context in which it is used.  

Bibliographic note

This is the peer reviewed version of the following article: Arnold, P., Sanaulla, S., Hampson, L.V., Davis, A., Tan, J., Cowen, R., Kaleem, M., Williams, A., Wadsworth, I. and Jaki, T. (2021), Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia. Pediatr Anaesth, 31: 548-556. https://doi.org/10.1111/pan.14164 which has been published in final form at https://onlinelibrary.wiley.com/doi/10.1111/pan.14164 This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.